Cover Image
市場調查報告書

Intra-Cellular Therapies, Inc. - 產品平台檢討

Intra-Cellular Therapies, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 293950
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Intra-Cellular Therapies, Inc. - 產品平台檢討 Intra-Cellular Therapies, Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月22日 內容資訊: 英文 35 Pages
簡介

Intra-Cellular Therapies, Inc.是總公司設置於美國的生物製藥企業。 正在開發中樞神經系統疾病的治療藥,開發平台擁有思覺失調症,躁鬱症,老年癡呆症,精神神經病變伴隨的睡眠障礙,自閉症,憂鬱症,其他心理障礙治療藥。該公司的磷酸二酯酶抑製劑平台是以治療思覺失調症和老年癡呆症、注意力陷缺、異動症、過動等認知障礙為標的。

本報告提供Intra-Cellular Therapies, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Intra-Cellular Therapies, Inc.的基本資料

  • Intra-Cellular Therapies, Inc.概要
  • 主要資訊
  • 企業資料

Intra-Cellular Therapies, Inc.:R&D概要

  • 主要的治療範圍

Intra-Cellular Therapies, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Intra-Cellular Therapies, Inc.:開發中產品概況

  • 後期階段產品開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Intra-Cellular Therapies, Inc.:藥物簡介

  • ITI-007
  • ITI-214
  • IC-200131
  • ITI-009
  • Small Molecule to Antagonize 5-HT2A Receptor for CNS Disorders
  • Small Molecules to Inhibit PDE1 for Central Nervous System Disorders
  • ITI-012
  • Small Molecules to Inhibit PDE2 for Alzheimer's Disease and Cognition Disorders
  • Small Molecules to Inhibit PDE9 for Alzhiemers Disease, Schizophrenia and Cognition Disorders

Intra-Cellular Therapies, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Intra-Cellular Therapies, Inc.:最新的開發平台資訊

Intra-Cellular Therapies, Inc.:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06972CDB

Summary

Global Markets Direct's, 'Intra-Cellular Therapies, Inc. - Product Pipeline Review - 2015', provides an overview of the Intra-Cellular Therapies, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Intra-Cellular Therapies, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Intra-Cellular Therapies, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Intra-Cellular Therapies, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Intra-Cellular Therapies, Inc.'s pipeline products

Reasons to buy

  • Evaluate Intra-Cellular Therapies, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Intra-Cellular Therapies, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Intra-Cellular Therapies, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Intra-Cellular Therapies, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Intra-Cellular Therapies, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Intra-Cellular Therapies, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Intra-Cellular Therapies, Inc. Snapshot
    • Intra-Cellular Therapies, Inc. Overview
    • Key Information
    • Key Facts
  • Intra-Cellular Therapies, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Intra-Cellular Therapies, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Intra-Cellular Therapies, Inc. - Pipeline Products Glance
    • Intra-Cellular Therapies, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Intra-Cellular Therapies, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Intra-Cellular Therapies, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Intra-Cellular Therapies, Inc. - Drug Profiles
    • ITI-007
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ITI-214
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IC-200131
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ITI-009
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Antagonize 5-HT2A Receptor for CNS Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE1 for Central Nervous System Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ITI-012
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE2 for Alzheimer's Disease and Cognition Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit PDE9 for Alzhiemers Disease, Schizophrenia and Cognition Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Intra-Cellular Therapies, Inc. - Pipeline Analysis
    • Intra-Cellular Therapies, Inc. - Pipeline Products by Target
    • Intra-Cellular Therapies, Inc. - Pipeline Products by Route of Administration
    • Intra-Cellular Therapies, Inc. - Pipeline Products by Molecule Type
    • Intra-Cellular Therapies, Inc. - Pipeline Products by Mechanism of Action
  • Intra-Cellular Therapies, Inc. - Recent Pipeline Updates
  • Intra-Cellular Therapies, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Intra-Cellular Therapies, Inc., Key Information
  • Intra-Cellular Therapies, Inc., Key Facts
  • Intra-Cellular Therapies, Inc. - Pipeline by Indication, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline by Stage of Development, 2015
  • Intra-Cellular Therapies, Inc. - Monotherapy Products in Pipeline, 2015
  • Intra-Cellular Therapies, Inc. - Phase III, 2015
  • Intra-Cellular Therapies, Inc. - Phase II, 2015
  • Intra-Cellular Therapies, Inc. - Phase I, 2015
  • Intra-Cellular Therapies, Inc. - Preclinical, 2015
  • Intra-Cellular Therapies, Inc. - Discovery, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline by Target, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline by Route of Administration, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline by Molecule Type, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Intra-Cellular Therapies, Inc. - Recent Pipeline Updates, 2015

List of Figures

  • Intra-Cellular Therapies, Inc. - Pipeline by Top 10 Indication, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline by Stage of Development, 2015
  • Intra-Cellular Therapies, Inc. - Monotherapy Products in Pipeline, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline by Top 10 Target, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Intra-Cellular Therapies, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top